18 results about "Endothelial dysfunction" patented technology

Provided is the use of a traditional Chinese medicine composition in preparation of a drug for preventing major adverse cardiac and cerebrovascular events after percutaneous coronary intervention and ameliorating myocardial injury and vascular endothelial dysfunction after percutaneous coronary intervention. The traditional Chinese medicine composition is composed of total salvianolic acid and total hawthorn triterpene acid.

The application discloses a method and application of knocking down ubiquitin-specific peptidase 7 protein, and belongs to the field of biological medicine. The method for knocking down the USP7 protein comprises: specifically inhibiting the expression of USP7 in endothelial cells through gene intervention, and the gene intervention means comprises shRNA, siRNA or recombinant virus carrier-mediated USP7 expression down-regulation. Further provided is a USP7 knockdown reagent for preparing a drug for treating endothelial cell inflammation or a cardiovascular disease, in particular, the USP7 knockdown reagent is a USP7 knockdown virus carrier containing a Cdh5 promoter; the cardiovascular disease comprises heart failure, myocardial infarction or ischemic cardiomyopathy. The application specifically knocks down the expression of USP7 in endothelial cells through gene intervention, significantly improves the migration, tube formation capacity and reduces the apoptosis of the endothelial cells, repairs endothelial dysfunction, the USP7 knockdown virus carrier is used for preparing a drug for treating a cardiovascular disease, and has important clinical value.

Subject of the invention are DPP3 binders for use in therapy or prevention of endothelial dysfunction in a patient wherein the level of Pro-Adrenomedullin or a fragment thereof in a sample of bodily fluid obtained from said patient is above a threshold, as well as methods of therapy guidance or therapy stratification or therapy monitoring of a treatment of a patient with a DPP3 binder, the methods comprising: providing a sample of bodily fluid of said patient; determining the level of Pro-Adrenomedullin or a fragment thereof in said sample; and comparing said level of Pro-Adrenomedullin or a fragment thereof to a threshold; wherein the level of Pro-Adrenomedullin or a fragment thereof in said sample being above said threshold is indicative that said patient requires treatment with a DPP3 binder, or wherein if said level of Pro-Adrenomedullin or a fragment thereof in said sample is above said threshold, said patient is treated with a DPP3 binder.

The invention belongs to the technical field of disease treatment, and particularly relates to a composition for regulating blood sugar and microvascular homeostasis and a preparation method thereof. The composition for regulating the blood sugar and the microvascular homeostasis is prepared from the following components in parts by mass: 380 to 520 parts of peony seed oil, 260 to 440 parts of dihydromyricetin and 0.025 to 0.062 part of chromium picolinate. The composition for regulating blood sugar and microvascular homeostasis can be used for protecting microvessels, regulating blood sugar, improving microcirculation of the whole body and preventing diabetic complications, and is suitable for preventing and treating diseases such as hyperglycemia, hyperlipidemia and glycolipid metabolism syndrome. Experiments on vascular endothelial dysfunction of obese rats show that the composition disclosed by the invention can be used for remarkably improving microvascular endothelial functions of the obese rats and effectively delaying rise of arterial blood pressure. Experiments on mouse diabetic cardiomyopathy find that the composition has a definite myocardial protection effect on DCM mice.

The present invention relates to pharmaceutical, dietary and / or food compositions exerting the ability to activate the endogenous production of hydrogen sulfide (H2S) so to feed the redox buffer capacity and to boost the natural ability to compensate both oxidative and reductive stress.The invention further relates to the use of the aforementioned compositions to correct signs of metabolic derangements such as: oxy-redox imbalances including reductive stress, mitochondrial dysfunction and bioenergetics, insulin resistance, endothelial dysfunction and hyperhomocysteinemia. Accordingly, the composition of the present invention can be used as a medicament for the treatment of hypertension, atherosclerosis and cardiovascular disease, erectile dysfunction, viral infections and inflammatory lung injuries, diabetes and PCOS, autoimmune diseases, neurodegeneration, repeated implantation failure and repeated miscarriage and infertility in both men and women.

The present application is directed to a method for the prediction of a risk of side effects and / or prediction of the severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cells in the frame of an immune effector cell therapy (IECT), and / or for assessing an effect of a treatment of side effects in a cancer patient that has been treated with immune effector cells in the frame of an IECT, the method comprising the steps of a) determining the level of at least one endothelial dysfunction biomarker in a sample of bodily fluid of said patient, and b) correlating said level of said at least one endothelial dysfunction biomarker in said sample to the risk of said side effects and / or the severity of said side effects in said patient and / or to the effect of said treatment of said side effects in said patient. Further aspects relate to corresponding methods stratification and medicaments for use in correponding treatment.

To provide a method for producing a cultured human corneal endothelial cell useful for an extremely long period of time for improving corneal opacity and hydration edema of a patient with corneal endothelial dysfunction.SOLUTION: A method for producing a human functional corneal endothelial cell capable of inducing a human corneal function when injected into an anterior chamber of a human eye, comprising (b) a step of proliferating and / or differentiating / maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress such as proliferation stress.SELECTED DRAWING: None

This invention proposes compounds of formula IA, IB, IC, ID, IE, IF, IG, IH, or IJ for the treatment or prevention of the following vascular endothelial dysfunction or vascular leakage diseases:

The application belongs to the technical field of medicine, and particularly relates to a blood vessel targeting anti-aging oral composition and application thereof. In view of problems such as endothelial dysfunction, matrix sclerosis and accumulation of senescent cells caused by vascular aging, the composition comprises active ingredients: beetroot extract, fisetin, salvianolic acid B, panax notoginseng total saponins, cocoa flavanol, pterostilbene, procyanidin B2, luteolin, nicotinamide riboside and astaxanthin. The composition is prepared by a process of adsorbing astaxanthin on beetroot extract, mixing other active ingredients, fillers and glidants after fisetin and salvianolic acid B are prepared into a solid dispersion, and sequentially cooperating each module, so that the pulse wave transmission velocity can be significantly reduced and the skeletal muscle capillary density can be increased, and the composition is mainly used for preparing a medicine for improving vascular stiffness, promoting microcirculation and removing vascular senescent cells.

The application discloses an application of perirenal adipose tissue exosomes rich in miRNA-486 in inducing endothelial dysfunction, wherein the perirenal adipose tissue exosomes are derived from adipose tissue around mammalian kidneys, rich in micro miRNA-486, have a particle size of 30-150 nanometers, have surface markers CD63, CD81 and TSG101, and have an expression level of the miRNA-486 in the perirenal adipose tissue exosomes increased by 3-5 times relative to a normal control, so that the perirenal adipose tissue exosomes can transmit the miRNA-486 to cells when being taken by vascular endothelial cells, and induce abnormal functions of the endothelial cells. The application proves that the perirenal adipose tissue exosomes rich in miR-486 can be taken by vascular endothelial cells in a specific manner through in-vivo and in-vitro experiments.

The invention relates to SLC22A6-targeted polypeptide, antibody, composition and application thereof in treatment and diagnosis of atherosclerosis, and researches find that expression of SLC22A6 in atherosclerotic endothelial cells is up-regulated, and glycolysis and lactic acid accumulation are promoted to drive H3K9 lactylation and activate SCD1 expression so as to mediate endothelial dysfunction and disease progression. Based on this, the invention provides a polypeptide and a monoclonal antibody which can specifically bind and inhibit the function of SLC22A6, and a pharmaceutical composition containing the polypeptide and the monoclonal antibody can be used for preventing or treating atherosclerosis. Meanwhile, the invention further provides a diagnostic kit containing the SLC22A6 detection reagent and a drug screening method taking the SLC22A6 as a target spot, and a new tool and strategy are provided for accurate intervention of atherosclerosis.

The present application is directed to a method for the prediction of a risk of side effects and / or prediction of the severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cells in the frame of an immune effector cell therapy (IECT), and / or for assessing an effect of a treatment of side effects in a cancer patient that has been treated with immune effector cells in the frame of an IECT, the method comprising the steps of a) determining the level of at least one endothelial dysfunction biomarker in a sample of bodily fluid of the patient, and b) correlating the level of the at least one endothelial dysfunction biomarker in the sample to the risk of the side effects and / or the severity of the side effects in the patient and / or to the effect of the treatment of the side effects in the patient. Further aspects relate to corresponding methods stratification and medicaments for use in corresponding treatment.

A method for determining a risk of sepsis in a patient is disclosed. The method includes collecting an exhaled breath sample, determining a NO concentration in the exhaled breath sample; and determining a sepsis risk score correlated to the NO concentration, wherein the sepsis risk score is indicative of a risk of a patient having or developing sepsis. The method may further include determining an additional measurement of the patient's vital statistics including one or more of: end tidal CO2, respiratory rate, pulse rate, body temperature, cognitive assessment score, systolic blood pressure, diastolic blood pressure, or hemoglobin oxygen saturation level, and further determining the sepsis risk score based on the additional measurement.

The disclosure provides compounds of Formula (I) having the structure:Compounds of Formula (I) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the disclosure are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and / or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and / or coronary artery disease), and / or multiple sclerosis.

This invention discloses the use of tanshinone or its pharmaceutically acceptable salts or derivatives in the preparation of PDK4 agonists. Tanshinone reverses EndMT and inhibits the progression of coronary artery disease atherosclerosis and endothelial dysfunction by restoring the metabolic regulator PDK4. It effectively prevents the progression of coronary artery disease by targeting anti-EndMT and metabolic regulation to improve abnormal endothelial function. The use of tanshinone in the preparation of drugs for treating angina pectoris in coronary artery disease opens up new application areas for tanshinone.

The invention discloses application of vitamin C, or stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof in preparation of drugs for preventing and treating vascular injury caused by microbial infection. The invention discloses a molecular mechanism that vitamin C regulates ATP11C expression and inhibits phosphatidylserine eversion so as to improve an endothelial barrier function, and provides a new action target for treatment of infection-related endothelial injury; cell experiments and animal experiments prove that the vitamin C has remarkable effects in the aspects of improving endothelial dysfunction caused by infection, reducing vascular leakage and increasing the survival rate of infected animals, and has good application prospects and clinical transformation values; the application of the vitamin C in vascular endothelial injury caused by staphylococcus aureus, hantavirus and dengue virus infection is clearly provided for the first time, and the new medical application of the vitamin C is expanded.

This invention provides a strain of Akkermansia myxophilus ( Akkermansia muciniphila The present invention provides a probiotic preparation comprising the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA). The Akkermansia myxophilus or its post-genetically modified organism (PGA) of the present invention can improve vascular endothelial cell function, increase testosterone secretion, and thus improve erectile dysfunction and reproductive capacity. The probiotic preparation of the present invention may comprise the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA) and yohimbine. This preparation can improve erectile dysfunction caused by vascular endothelial dysfunction, improve reproductive function in aged mice, and the components in this preparation have a synergistic effect.